Anti-Human FAP Recombinant Antibody (Sibrotuzumab) (CAT#: TAB-211)

Recombinant monoclonal antibody to FAP. Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Murine and human multipotent BMSCs express FAP and are recognized by T cells expressing FAP-reactive CARs.

Figure 1 Murine and human multipotent BMSCs express FAP and are recognized by T cells expressing FAP-reactive CARs.

Passage-5 in vitro–expanded murine BMSCs were stained with antibodies specific for Sca-1, PDGFR-α, and FAp< and assessed by flow cytometry (A). "Q" represents quadrant. Solid lines are isotype controls and filled histograms are FAP stained. UnTd or FAP5-CAR Td T cells were cultured overnight with murine BMSCs and supernatants were assessed for IFN-γ by ELISA (B), and cells were further analyzed for expression of CD107a and production of IFN-γ and TNF by ICS (C). Mean ± SD. Data are representative of two independent experiments. Flow cytometric phenotype of in vitro–expanded human BMSCs derived from three different donors (D). BMSCs from D were stained with the FAP-specific monoclonal antibodies Sibrotuzumab (E) and FAP5 (F) and assessed by flow cytometry. Solid lines are isotype or secondary antibody controls and filled histograms are FAP or Sibrotuzumab stained. UnTd or Sibro-CAR Td T cells were cultured overnight with BMSCs and the supernatants assessed for IFN-γ by ELISA (G), and cells were further analyzed for CD107a expression and IFN-γ and TNF production by ICS (H). Mean ± SD. Similar results were seen with two additional T cell donors.

Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C. C. R., Restifo, N. P., & Rosenberg, S. A. (2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Journal of Experimental Medicine, jem-20130110.

Figure 2 IHC staining for FAP in various human tumors, and design and in vitro activity of FAP-reactive CARs.

Figure 2 IHC staining for FAP in various human tumors, and design and in vitro activity of FAP-reactive CARs.

Representative IHC staining for FAP in human melanoma (A), colorectal (B), pancreatic (C), and breast (D) adenocarcinomas. Isotype stains were negative (not depicted). Bars: 400 µm (A); 200 µm (B–D). Schematic of the FAP-reactive CAR constructs FAP5-CAR (E) and Sibro-CAR (F). LS, GM-CSFR leader sequence; VH and VL, variable heavy and light chains; L, 218 linker; CD8, transmembrane domain; CD28, 4-1BB, and CD3-ζ, intracellular signaling domains; m, murine; h, human. Both constructs were cloned into the MSGV1 retroviral vector. Retrovirus containing FAP5-CAR or Sibro-CAR constructs were generated and used to transduce mouse and human T cells, respectively, and flow cytometry was used to assess transduction efficiency at day 2 after transduction for FAP5-CAR (G) and day 8–10 after transduction for Sibro-CAR (H). Solid line is isotype control and filled histogram is FAP5 or Sibrotuzumab stained. Day 5-stimulated untransduced (UnTd) and FAP5-CAR–transduced (Td) mouse T cells were assessed for reactivity against plate-bound BSA, α-CD3 mAb, and recombinant human FAP (r-huFAP), and against HEK293 cell lines expressing or not expressing FAP. After an overnight stimulation, supernatants were assessed for IFN-γ with an IFN-γ ELISA (I), and cells were further assessed for cell surface CD107a expression, and production of IFN-γ and TNF by ICS (J). For ICS, cells are gated on FAP5-CAR Td cells. Day ∼14-stimulated UnTd or Sibro-CAR Td human T cells were assessed for in vitro reactivity as described for mouse. IFN-γ ELISA (K), and ICS results gated on Sibro-CAR Td T cells (L) are shown. Mean ± SD. All results are representative of at least three independent experiments.

Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C. C. R., Restifo, N. P., & Rosenberg, S. A. (2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Journal of Experimental Medicine, jem-20130110.


Specifications

  • Immunogen
  • A synthetic peptide derived from human Fibroblast activation protein, alpha.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, WB
  • CAS
  • 216669-97-5
  • Generic Name
  • Sibrotuzumab
  • Related Disease
  • Unknown

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The FAP antibody has been reported in applications of FC, IHC.
    FC: The secondary detection antibody was PE-conjugated AffiniPure F(ab')2 fragment donkey anti–mouse IgG, and PE-conjugated AffiniPure F(ab')2 fragment donkey anti–human IgG used at 1:100 dilution to detect the FAP5 and Sibrotuzumab antibodies, respectively.

Target

  • Alternative Names
  • Sibrotuzumab;216669-97-5;BIBH 1;humanized F19;FAP;fibroblast activation protein, alpha;seprase;DPPIV;integral membrane serine protease;170 kDa melanoma membrane-bound gelatinase;FAPA;DKFZp686G13158;

Related Resources

  • Biosimilar Overview
Please refer to Sibrotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Sibrotuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Sibrotuzumab"

Afuco™ Anti-FAP ADCC Recombinant Antibody (Sibrotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to FAP. Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP.

See other products for "Fap"

Select a product category from the dropdown menu below to view related products.
Please select product type
Human Antibody Fc Glycosylation Low- or Non-fucosylated Oligosaccharide Recombinant Antibody scFv Fragment Antibody Fab Fragment Antibody Single-domain Antibody ADCC Enhanced Antibody MHC Tetramer for Cancer

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-211. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare